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dogs from households in Italy
E. I. Patterson 1, G. Elia2, A. Grassi3, A. Giordano4, C. Desario2, M. Medardo5, S. L. Smith6, E. R. Anderson1,
T. Prince7, G. T. Patterson 6, E. Lorusso2, M. S. Lucente2, G. Lanave2, S. Lauzi4, U. Bonfanti5, A. Stranieri4,
V. Martella2, F. Solari Basano8, V. R. Barrs9, A. D. Radford6, U. Agrimi10, G. L. Hughes 1, S. Paltrinieri 4 &
N. Decaro 2✉
SARS-CoV-2 emerged from animals and is now easily transmitted between people. Sporadic
detection of natural cases in animals alongside successful experimental infections of pets,
such as cats, ferrets and dogs, raises questions about the susceptibility of animals under
natural conditions of pet ownership. Here, we report a large-scale study to assess SARS-CoV-
2 infection in 919 companion animals living in northern Italy, sampled at a time of frequent
human infection. No animals tested PCR positive. However, 3.3% of dogs and 5.8% of cats
had measurable SARS-CoV-2 neutralizing antibody titers, with dogs from COVID-19 positive
households being significantly more likely to test positive than those from COVID-19 negative
households. Understanding risk factors associated with this and their potential to infect other
species requires urgent investigation.
https://doi.org/10.1038/s41467-020-20097-0 OPEN
1 Centre for Neglected Tropical Disease, Departments of Vector Biology and Tropical Disease Biology, Liverpool School of Tropical Medicine, Pembroke Place,
Liverpool L3 5QA, UK. 2Department of Veterinary Medicine, University of Bari Aldo Moro, Strada Prov. per Casamassima Km 3, 70010 Valenzano, BA, Italy.
3 I-VET srl, Laboratorio di Analisi Veterinarie, Via Ettore Majorana, 10 - 25020 Flero, BS, Italy. 4 Department of Veterinary Medicine, Veterinary Teaching
Hospital, University of Milan, Via dell’Università 6, 26900 Lodi, Italy. 5 La Vallonèa Veterinary Diagnostic Laboratory, via G. Sirtori 9, 20017 Passirana di Rho,
MI, Italy. 6 Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Leahurst Campus, Chester High Road, Neston CH64 7TE, UK.
7 NIHR Health Protection Unit in Emerging and Zoonotic Infections, Department of Clinical Infection, Microbiology and Immunology, University of Liverpool,
Liverpool, UK. 8Arcoblu s.r.l., via Alessandro Milesi 5, 20133 Milan, Italy. 9 City University’s Jockey Club College of Veterinary Medicine and Life Sciences, 5/
F, Block 1A, To Yuen Building, 31 To Yuen Street, Kowloon, Hong Kong. 10 Department of Food Safety, Nutrition and Veterinary Public Health, Istituto
Superiore di Sanità, Viale Regina Elena, 299, 00161 Rome, Italy. ✉email: nicola.decaro@uniba.it
NATURE COMMUNICATIONS |         (2020) 11:6231 | https://doi.org/10.1038/s41467-020-20097-0 | www.nature.com/naturecommunications 1
12
34
56
78
9
0
()
:,;
Cases of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) infection were detected in late December2019 in Wuhan, Hubei Province, China1, possibly as a
spillover from bats to humans2, and rapidly spread worldwide
becoming a pandemic3. Although the virus is believed to spread
almost exclusively by human-to-human transmission, there are
concerns that some animal species may contribute to the ongoing
SARS-CoV-2 pandemic4. To date, sporadic cases of SARS-CoV-2
infection have been reported in dogs and cats. These include
detection of SARS-CoV-2 RNA in respiratory and/or fecal spe-
cimens of dogs and cats with or without clinical signs5–7, as well
as of specific antibodies in sera from pets from coronavirus dis-
ease 2019 (COVID-19)-affected areas7,8. In addition, experi-
mental infection of various animal species has demonstrated that
although dogs appear poorly susceptible to SARS-CoV-2 infec-
tion, developing asymptomatic infections and shedding low titer
or no virus, cats develop respiratory pathology and shed high
titers of SARS-CoV-2, even being able to infect in-contact
animals9,10. Wide-scale testing of susceptible species is needed to
assess the extent of animal infection under more natural condi-
tions of husbandry. Here we conducted an extensive epidemio-
logical survey from March to May 2020 in cats and dogs living in
Italy, either in SARS-CoV-2-positive households or living in
geographic areas that were severely affected by COVID-19. To
our knowledge, this is the largest study to investigate SARS-CoV-
2 in companion animals to date.
Results
All animals were sampled by their private veterinary surgeon
during routine healthcare visits between 15 March and 11 May
2020 (Source data S1). Sampling of animals for this study was
approved by the Ethics Committee of the Department of Veter-
inary Medicine, University of Bari, Italy (approval number 15/
2020). A total of 603 dogs and 316 cats were sampled from dif-
ferent Italian regions, mostly Lombardy (476 dogs, 187 cats).
Animals were sampled either from regions severely affected by
COVID-19 outbreaks in humans or from those that offered
convenient access to samples. Oropharyngeal (303 dogs, 173
cats), nasal (183 dogs, 78 cats), and/or rectal (66 dogs, 30 cats)
swabs were collected from a total of 494 pets using synthetic fiber
swabs (Table 1). For 340 dogs and 188 cats, full signalment and
clinical history were collected, including breed, sex, age, exposure
to COVID-19-infected humans in the previous 2 weeks (COVID-
19-positive household, suspected COVID-19-positive household
but not confirmed by specific assay, and COVID-19-negative
household), and the presence of respiratory signs (cough, sneez-
ing, conjunctivitis, nasal and/or ocular discharge). Pets living with
SARS-CoV-2-infected patients included 47 dogs and 22 cats for
serology and 64 dogs and 57 cats for molecular investigations,
with a single animal being sampled from each COVID-19-
positive household.
Sera were available for 188 dogs and 63 cats for which complete
signalment, history, and location were available (Fig. 1). Addi-
tional sera were collected from diagnostic laboratories for 263
dogs and 128 cats from the affected areas, but which lacked
further historical information.
Detection of SARS-CoV-2 RNA used two real-time reverse-
transcription PCR (RT-PCR) assays targeting nucleoprotein and
envelope protein genes11. Plaque reduction neutralization tests
(PRNTs)12 were performed with SARS-CoV-2/human/Liverpool/
REMRQ0001/2020 isolate13. PRNT80 was determined by the
highest dilution with ≥80% reduction in plaques compared to the
control.
All 494 animals from which at least a swab was available tested
negative for SARS-CoV-2 RNA, including 38 cats and 38 dogs
that showed respiratory disease at the time of sampling, sug-
gesting the absence of active SARS-CoV-2 infection in the tested
animals. In addition, 64 of these dogs and 57 of the cats that
tested negative were living in households previously confirmed as
having had COVID-19 and 14 animals (11 cats and 3 dogs) from
COVID-19 households were displaying respiratory signs at the
time of sampling.
SARS-CoV-2-neutralizing antibodies were detected in 15 dogs
(3.3%, 15/451) and 11 cats (5.8%, 11/191), with titers ranging
from 1:20 to 1:160 and from 1:20 to 1:1280 in dogs and cats,
respectively. Of samples from households with known COVID-19
status, neutralizing antibodies were detected in 6 of 47 dogs
(12.8%) and 1 of 22 cats (4.5%) from COVID-19-positive
households, 1 of 7 dogs (14.3%) and 0 of 3 cats (0%) from sus-
pected COVID-19-positive households, and 2 of 133 dogs (1.5%)
and 1 of 38 cats (2.6%) from COVID-19-negative households
(Table 2). For those 423 animals where an age was recorded, 0 of
30 aged <1 year (0.0%), 6 of 92 aged 1–3 years (6.5%), 3 of 102
aged 4–7 years (2.9%), and 6 of 199 aged 8 years and over (3.0%)
tested positive. None of the animals with neutralizing antibodies
displayed respiratory signs at the time of sampling.
Reference sera or ascitic fluids from animals previously shown
to be positive for canine enteric coronavirus14 (three sera), canine
respiratory coronavirus15 (three sera), and feline coronavirus16
(three ascitic fluids) tested negative by the PRNT assay for SARS-
CoV-2, confirming the specificity of the obtained results8.
Dogs were significantly more likely to test positive for SARS-
CoV-2-neutralizing antibodies if they came from a known
COVID-19-positive household (Fisher’s exact test, p= 0.004) or
were male (Fisher’s exact test, p= 0.045), whereas there was
insufficient data to assess any correlation with the neuter status,
as this was reported only for 1 seropositive bitch. For provinces in
the Lombardy region where at least ten samples were available,
there was a positive trend between the proportion of dogs that
tested positive and the recorded burden of human disease
(Spearman’s r= 0.771, p= 0.103) (Fig. 2) (Source data S2). A
similar association was observed for cats (Spearman’s r= 0.696,
p= 0.125).
Discussion
Following its original probable transmission to humans from
animals, SARS-CoV-2 has spread globally within the human
population with devastating health and economic impacts. To
date, SARS-CoV-2 has been sporadically detected in naturally
infected dogs and cats, most of which were living in close contact
with infected humans. Most studies of companion animals are
small in nature, likely because of an inevitable research focus on
human disease. Our results from this extensive study of SARS-
CoV-2 infection in owned pets living in areas where viral
Table 1 Sample type distribution for detection of SARS-CoV-2
RNA.
Sample type Dogs Cats Total
OP only 131 98 229
N only 11 3 14
R only 0 0 0
OP+N 106 49 155
OP+ R 0 4 4
N+ R 0 0 0
O+N+ R 66 26 92
Total 314 180 494
N nasal swab, OP oropharyngeal swab, R rectal swab.
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transmission was active in the human population confirms field
observations that both cats and dogs can seroconvert under the
normal conditions of pet ownership.
The link between SARS-CoV-2 household infection and a pet’s
seropositivity was only apparent for dogs, possibly suggesting
greater interaction between positive people and their household
dogs as compared to cats. This contrasts experimental studies
where dogs were less susceptible to infection9. However, this
finding could be also reflective of the small numbers of
seropositive cats identified. In addition, a higher proportion of
male dogs were seropositive compared to female dogs, but also in
this case the results could have been biased by the small size of
positive animals. In fact, neuter status was unknown for the
majority of seropositive animals, which prevented a full com-
parison with the situation in humans. Future studies in animals
and humans should investigate whether this phenomenon is
based in physiological or behavioral differences between males
and females. Although there are clear gender differences in out-
comes in human COVID-19 infections, with males at higher risk
of severe disease, there seems to be no evidence for a difference in
infection risk17. None of the 30 juvenile animals, <1 year of age,
tested positive. Our findings are consistent with reports of other
seropositive naturally exposed cats and dogs, which were all
adult6,7, and in experimentally infected adult cats and dogs where
clinical signs were not displayed18. However, in cats aged <1 year
a higher susceptibility to SARS-CoV-2 infection was observed at
70–100 days than at 8 months of age9.
In contrast to the serology results, all animals tested negative by
PCR, including those animals living in households with con-
firmed COVID-19 human infection and those with and without
respiratory signs. This suggests that although pet animals can
seroconvert, they may shed virus for relatively short periods of
time. In experimental studies, cats stopped shedding virus by
10 days post infection (dpi) and developed neutralizing antibody
responses by 7–13 dpi9,18. Similar results were reported in
experimental infection of dogs, in which virus was detected in
feces up to 6 dpi, but not in oropharyngeal swabs6. However, in a
naturally infected Pomeranian dog, SARS-CoV-2 RNA was
detected from nasal swabs by quantitative RT-PCR for at least
13 days at low titer, whereas the virus was not detected in fecal/
rectal samples7, suggesting that virus shedding patterns may vary
in some animals. Half of the challenged dogs had detectable
antibodies by 14 dpi. These studies and our own highlight similar
challenges in detecting SARS-CoV-2 infection that exist for both
humans and animals19. It is not possible with our field data set to
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Fig. 1 Distribution of dog and cat samples assayed for neutralizing antibody titer across Italy and the region of Lombardy. Data on human COVID-19
cases from the Italian Department of Civil Protection as of 31 May 2020 and population data from the Italian National Institute of Statistics (ISTAT),
January 2019. Source data are provided as a Source Data file.
Table 2 Seropositivity among dogs and cats, split into risk
factor groupings where data were availablea.
Dogs Cats
Risk factor No.+
(total)
% p No.+
(total)
% p
Household 0.004 1.000
Covid+ 6 (47) 12.8% 1 (22) 4.5%
Covid− 2 (133) 1.5% 1 (38) 2.6%
Suspected
Covid+
1 (7) 14.3% 0 (3) 0.0%
Sex 0.045 0.492
Male 7 (83) 8.4% 2 (31) 6.5%
Female 2 (105) 1.9% 0 (30) 0.0%
Age (years) na na
<1 0 (20) 0.0% 0 (9) 0.0%
1–3 5 (70) 7.1% 1 (22) 4.5%
4–7 2 (83) 2.4% 1 (19) 5.3%
8+ 4 (137) 2.9% 2 (62) 3.2%
Unknown 4 (141) 2.8% 7 (78) 9.0%
aFor household and sex, p-value determined by two-sided Fisher’s exact test. Household COVID
+ defined as one or more members of a household with a confirmed positive COVID-19 test.
All the information was not available for all the animals. Both household (p= 0.004) and sex
(p= 0.045) were associated with COVID seropositivity among dogs, whereas neither
household (p= 1.000) nor sex (p= 0.492) were associated with COVID seropositivity
among cats.
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estimate the time of infection in animals that were seropositive,
and restrictions on human and animal movement during the
pandemic may have delayed visits to veterinary practitioners
where sampling occurred. We advocate the inclusion of pets in
ongoing assessments of community and household shedding to
improve detection of active infection.
In this extensive epidemiological survey of SARS-CoV-2, we
found that companion animals living in areas of high human
infection have been exposed to SARS-CoV-2, thus confirming
previous reports of natural infections of dogs and cats with the
novel coronavirus. Our results suggest that dogs warrant further
investigation regarding SARS-CoV-2 susceptibility, although
higher antibody titers were detected in cats, which is in agree-
ment with previous studies, suggesting that these animals are
most susceptible to SARS-CoV-2 infection9,18. We also observed
seropositivity rates in animals comparable to those of humans
via community sampling at a similar time in European coun-
tries20–22. This suggests that infection in companion animals is
not unusual. Based on current knowledge, it is unlikely that
infected pets play an active role in SARS-CoV-2 transmission to
humans. However, animal-to-human transmission may be more
likely under certain environmental conditions, such as the high
animal population densities encountered on infected mink
farms23. As and when human transmission becomes rarer and
contact tracing becomes more accessible, serological surveillance
of pets may be advocated to develop a holistic picture of com-
munity disease dynamics and ensure that all transmission
opportunities are terminated.
Methods
Samples. All animals were sampled by their private veterinary surgeon during a
healthcare visit for other reasons. A total of 603 dogs and 316 cats were sampled
from different Italian regions, mostly Lombardy (476 dogs, 187 cats). Animals were
sampled either from regions severely affected by COVID-19 outbreaks in humans
or from those that offered convenient access to samples. Oropharyngeal (303 dogs,
173 cats), nasal (183 dogs, 78 cats), and/or rectal (66 dogs, 30 cats) swabs were
collected from a total of 494 pets using synthetic fiber swabs (Table 1). Orophar-
yngeal swabs were collected by inserting the swab into the posterior pharynx and
tonsillar areas. For collection of nasal secretions, the same swab was inserted into
each nostril and rotated in order to be saturated by the nasal fluid. Rectal swabs
were collected by inserting the swab 1–2 cm past the anal verge and rotating the
swab gently 360°. After swabbing each swab was immersed in 1.5 ml of viral
transport medium.
For 340 dogs and 188 cats, full signalment and clinical history were available,
including breed, sex, age, exposure to COVID-19-infected humans (COVID-19-
positive household, suspected COVID-19-positive household but not confirmed by
specific assay, and COVID-19-negative household), the presence of respiratory
signs (cough, sneezing, conjunctivitis, nasal, and/or ocular discharge).
Sera were available for 188 dogs and 63 cats for which complete signalment,
history, and location were available (Fig. 1). Additional sera were collected from
diagnostic laboratories for 263 dogs and 128 cats from the affected areas, but which
lacked further historical information.
Sampling of animals for this study was approved by the Ethics Committee of
the Department of Veterinary Medicine, University of Bari, Italy (approval number
15/2020).
Polymerase chain reaction. Sample preparation and RNA extraction were carried
out in the biosafety level 3 containment laboratory at the Department of Veterinary
Medicine, University of Bari, Italy. Detection of SARS-CoV-2 RNA used two real-
time RT-PCR assays targeting nucleoprotein and envelope protein genes11. Briefly,
a one-step method was adopted using the Superscript III one-step RT-PCR system
with Platinum Taq Polymerase (Invitrogen srl, Milan, Italy) and the following 50-µl
mixture: 25 µl of master mix, 400 nM (E_Sarbeco_F, E_Sarbeco_R), 600 nM
(N_Sarbeco_F), or 800 nM (N_Sarbeco_R) of primers, 200 nM of probes (E_Sar-
beco_P1 or N_Sarbeco_P) (Supplementary Table 1), and 10 μl of template RNA.
The thermal profile consisted of incubation at 55 °C for 10 min for reverse tran-
scription, followed by 95 °C for 3 min and then 45 cycles of 95 °C for 15 s, 58 °C
for 30 s.
Plaque reduction neutralization test. The SARS-CoV-2/human/Liverpool/
REMRQ0001/2020 isolate was cultured in Vero E6 cells13. For PRNT12, sera were
heat inactivated at 56 °C for 1 h and stored at −20 °C until use. Dulbecco’s minimal
essential medium containing 2% fetal bovine serum and 0.05 mg/mL gentamicin
was used for serial twofold dilutions of serum. SARS-CoV-2 at 800 PFU/mL was
added to an equal volume of diluted serum and incubated at 37 °C for 1 h. The
virus serum dilution was inoculated onto Vero E6 cells, incubated at 37 °C for 1 h,
and overlaid as in standard plaque assays. Cells were incubated for 48 h at 37 °C
and 5% CO2 then fixed with 10% formalin and stained with 0.05% crystal violet
solution. PRNT80 was determined by the highest dilution with 80% reduction in
plaques compared to the control. Samples with detectable neutralizing antibody
titer were repeated as technical replicates for confirmation.
Data analysis. Fisher’s exact test was used to analyze differences in antibody
detection from households with known COVID-19 infection status, and antibody
detection from male and female animals. Spearman’s correlation was used to
analyze the relationship between human COVID-19 case numbers and detection of
antibodies in animals. All statistical analyses were performed in GraphPad Prism 6.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The authors declare that the data supporting the findings of this study are available
within the article and its Supplementary Information files, or are available from the
authors upon request. Source data are provided with this paper.
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